Sales are strong, especially for Stribild, but Gilead is planning ahead for the patent expiration of Viread and replacing it in combo regimens with a new formulation of tenofovir that offers enhanced therapeutic benefits.
Most of its headlines are generated by its blockbuster revenues in hepatitis C these days, but Gilead Sciences Inc. reminded investors and biopharma industry watchers Oct. 27 not to overlook the steady progress of its late-stage pipeline in HIV, spurred by tenofovir alafenamide fumarate (TAF), a reformulation of its HIV backbone drug Viread.
The Foster City, Calif.-based firm said on its third quarter sales and earnings call that it expects approvals of three...
Business Group on Health annual employer survey highlights fast-growing Rx costs, led by the GLP-1 drugs, and payer strategies for controlling them. Policy prescriptions are unclear, though, since employers are loath to leave PBMs and nervous about pending changes to Medicare and Medicaid.
Reviewers were not targeted by the FDA reduction in force, but increasing attrition and difficulties hiring new staff still do not seem to have impacted new and generic drug approval totals.
Complaint names LillyDirect in action targeting the company’s free nurse and reimbursement support programs for health care providers.
